Dr. Feras Hamdan, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 9
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 178
Licensed in California since 2024, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
OH license 35.140087 · CA license A195958 (first issued 2024; current) -
Internal Medicine Physician
CA license A195958 (first issued 2024; current) · OH license 35.140087 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Quick Med Urgent Care LLC (53 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 178
- Services billed
- 391
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 65 | 62 |
| New patient office or other outpatient visit, 30-44 minutes | 43 | 43 |
| Urinalysis, manual test | 19 | 19 |
| Established patient office or other outpatient visit, 30-39 minutes | 18 | 18 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 13 | 13 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amoxicillin Other prescribers in Cleveland, OH | 180 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Cleveland, OH | 79 |
| Methylprednisolone Other prescribers in Cleveland, OH | 78 |
| Paxlovid (nirmatrelvir/ritonavir) Other prescribers in Cleveland, OH | 58 |
| Azithromycin Other prescribers in Cleveland, OH | 43 |
| Doxycycline Hyclate Other prescribers in Cleveland, OH | 42 |
| Cephalexin Other prescribers in Cleveland, OH | 41 |
| Fluticasone Propionate Other prescribers in Cleveland, OH | 40 |
| Buprenorphine-Naloxone (buprenorphine hcl/naloxone hcl) Other prescribers in Cleveland, OH | 34 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $84.22 in total to this clinician.
| Lundbeck LLC | $69.96 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $14.26 |
| Food and Beverage | $84.22 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $26,395 in research payments for these studies, mostly to the institutions running them.
- A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
H. Lundbeck A S - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.